tafluprost ophthalmic (Zioptan)

Introduction

FDA-approved Feb 10, 2012

Indications

• increased intraocular pressure
• open-angle glaucoma

Contraindications

• pregnancy category C

Dosage

• 1 drop in affected eye(s) once daily in the evening

ophthalmic solution 0.0015%

Adverse effects

• conjunctival hyperemia (4-20%)
• darkening of the iris (may be permanent)
• darkening of the eyelid (may be reversible)
• eyelash growth

Mechanism of action

• fluorinated analog of prostaglandin F2-alpha
• prostaglandin F2-alpha receptor agonists are throught to reduce intraocular pressure by increasing uveosceral outflow

More general terms

• tafluprost
• ophthalmic agent (eyedrops)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9868491
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9978917
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53394479
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=23725062